Prof. Ravi Venkata Durvasula
University of New Mexico School of Medicine, USA

Email: tuanravi@gmail.com

Qualifications

1989 M.D., McGill University, Canada
1985 B.Sc., McGill University, Canada

Publications (Selected)

1. Rueda Prada L, Gorasevic M, Gavrancic T, Rajani AJ, Sluzevich JC, Nair-Collins S, Durvasula RV. A Report of Two Uncommon Cases of Mycobacterium chelonae with Localized and Disseminated Skin and Soft Tissue Infection. Infect Dis Rep. 2025 Feb 8; 17 (1) Epub 2025 Feb 08
2. Attieh RM, Roach D, Wadei HM, Parikh N, Me HM, Durvasula RV, Oring J. Case Report: Early-Onset Adenovirus Nephritis Without Hemorrhagic Cystitis Following Kidney Transplantation. Transplant Proc. 2024 Jun; 56 (5):1196-1199 Epub 2024 June 08
3. Rajani AJ, Raval DM, Chitale RA, Kempaiah P, Elwasila SM, Durvasula R, Oring J. Half a Century in Hiding: A Unique Case of Tuberculoid Leprosy with an Unprecedented Incubation Period. Am J Case Rep. 2024 Feb 14; 25:e942048
4. Rajani AJ, Raval D, Chitale R, Durvasula R, Oring J, Powers R. A rare case of scedosporium apiospermum osteomyelitis in an immunocompetent patient. IDCases. 2024; 35:e01929 Epub 2024 Jan 30
5. Godart GA, Elwasila SM, Durvasula RV. A rare case of candida osteomyelitis of the mandible associated with osteoradionecrosis and biofilm formation. IDCases. 2024; 37:e02029 Epub 2024 July 18
6. Rajani AJ, Roach D, Raval D, Amin J, Kempaiah P, Chitale R, Durvasula R, Oring J. A systemic review of Mycobacterium nebraskense case reports up to october 2023, featuring our unique case study. Int J Mycobacteriol. 2023 Oct-Dec; 12 (4):443-447
7. Westlund KN, Montera MA, Goins AE, Alles SRA, Afaghpour-Becklund M, Bartel R, Durvasula R, Kunamneni A. Corrigendum to "Single-chain fragment variable antibody targeting cholecystokinin-B receptor for pain reduction" [Neurobiol. Pain 10 (2021) 100067]. Neurobiol Pain. 2023 Aug-Dec; 14:100127 Epub 2023 Apr 05
8. Kunamneni A, Montera MA, Durvasula R, Alles SRA, Goyal S, Westlund KN. Rapid Generation and Molecular Docking Analysis of Single-Chain Fragment Variable (scFv) Antibody Selected by Ribosome Display Targeting Cholecystokinin B Receptor (CCK-BR) for Reduction of Chronic Neuropathic Pain. Int J Mol Sci. 2023 Jul 3; 24 (13) Epub 2023 July 03
9. Prabhakaran D, Day GS, Munipalli B, Rush BK, Pudalov L, Niazi SK, Brennan E, Powers HR, Durvasula R, Athreya A, Blackmon K. Neurophenotypes of COVID-19: Risk factors and recovery outcomes. Brain Behav Immun Health. 2023 Jul; 30:100648 Epub 2023 June 04
10. Gupta Y, Savytskyi OV, Coban M, Venugopal A, Pleqi V, Weber CA, Chitale R, Durvasula R, Hopkins C, Kempaiah P, Caulfield TR. Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. Mol Aspects Med. 2023 Jun; 91:101151 Epub 2022 Oct 28
11. Asiedu SO, Gupta Y, Nicolaescu V, Gula H, Caulfield TR, Durvasula R, Kempaiah P, Kwofie SK, Wilson MD. Mycolactone: A Broad Spectrum Multitarget Antiviral Active in the Picomolar Range for COVID-19 Prevention and Cure. Int J Mol Sci. 2023 Apr 12; 24 (8)
12. Mohammad TSH, Gupta Y, Reidl CT, Nicolaescu V, Gula H, Durvasula R, Kempaiah P, Becker DP. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. Int J Mol Sci. 2023 Mar 7; 24 (6) Epub 2023 Mar 07
13. Gupta Y, Sharma N, Singh S, Romero JG, Rajendran V, Mogire RM, Kashif M, Beach J, Jeske W, Poonam Poonam, Ogutu BR, Kanzok SM, Akala HM, Legac J, Rosenthal PJ, Rademacher DJ, Durvasula R, Singh AP, Rathi B, Kempaiah P. The Multistage Antimalarial Compound Calxinin Perturbates P. falciparum Ca(2+) Homeostasis by Targeting a Unique Ion Channel. Pharmaceutics. 2022 Jun 28; 14 (7) Epub 2022 June 28
14. Gupta Y, Goicoechea S, Romero JG, Mathur R, Caulfield TR, Becker DP, Durvasula R, Kempaiah P. Repurposing Lansoprazole and Posaconazole to treat leishmaniasis: Integration of in vitro testing, pharmacological corroboration, and mechanisms of action. J Food Drug Anal. 2022 Mar 15; 30 (1):128-149
15. Gupta Y, Maciorowski D, Medernach B, Becker DP, Durvasula R, Libertin CR, Kempaiah P. Iron dysregulation in COVID-19 and reciprocal evolution of SARS-CoV-2: Natura nihil frustra facit. J Cell Biochem. 2022 Mar; 123 (3):601-619 Epub 2022 Jan 08
16. Verma JS, Libertin CR, Gupta Y, Khanna G, Kumar R, Arora BS, Krishna L, Fasina FO, Hittner JB, Antoniades A, van Regenmortel MHV, Durvasula R, Kempaiah P, Rivas AL. Multi-Cellular Immunological Interactions Associated With COVID-19 Infections. Front Immunol. 2022; 13:794006 Epub 2022 Feb 24
17. Gupta Y, Goicoechea S, Pearce CM, Mathur R, Romero JG, Kwofie SK, Weyenberg MC, Daravath B, Sharma N, Poonam, Akala HM, Kanzok SM, Durvasula R, Rathi B, Kempaiah P. The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites. Med Res Rev. 2022 Jan; 42(1):56-82. Epub 2021 Apr 13.
18. Westlund KN, Montera MA, Goins AE, Alles SRA, Suri N, McIlwrath SL, Bartel R, Durvasula RV, Kunamneni A. Single-Dose P2 X4R Single-Chain Fragment Variable Antibody Permanently Reverses Chronic Pain in Male Mice. Int J Mol Sci. 2021 Dec 19; 22(24).
19. Gupta Y, Maciorowski D, Zak SE, Jones KA, Kathayat RS, Azizi SA, Mathur R, Pearce CM, Ilc DJ, Husein H, Herbert AS, Bharti A, Rathi B, Durvasula R, Becker DP, Dickinson BC, Dye JM, Kempaiah P. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods. 2021 Nov; 195:57-71 Epub 2021 Jan 14
20. Kumar S, Gupta Y, Zak SE, Upadhyay C, Sharma N, Herbert AS, Durvasula R, Potemkin V, Dye JM, Poonam Poonam, Kempaiah P, Rathi B. A novel compound active against SARS-CoV-2 targeting uridylate-specific endoribonuclease (NendoU/NSP15): in silico and in vitro investigations. RSC Med Chem. 2021 Oct 20; 12 (10):1757-1764 Epub 2021 Aug 18

Profile Details

https://vivo.health.unm.edu/display/n7163

https://www.mayo.edu/research/faculty/durvasula-ravi-v-m-d/bio-20521871

https://www.mayoclinic.org/biographies/durvasula-ravi-v-m-d/bio-20509479